CD8A and cancer: Our results confirm that CD8+ T-cells, when treated with MEKi and nivolumab in vitro, become T-cells with high, stable CCR7 expression, are resistant to the cytotoxic effect of cancer cells, and are distinct from naive T-cells (Figures S1 and S2).